Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention.
Groupes témoinsMéthodes de recherche
#2
Quel est le rôle d'un groupe témoin ?
Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité.
Groupes témoinsÉvaluation des traitements
#3
Comment choisir un groupe témoin ?
Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité.
Groupes témoinsCritères d'inclusion
#4
Les groupes témoins sont-ils toujours nécessaires ?
Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques.
Groupes témoinsEssais cliniques
Symptômes
2
#1
Les groupes témoins montrent-ils des symptômes ?
Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement.
Groupes témoinsSymptômes
#2
Comment les symptômes sont-ils évalués ?
Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes.
Évaluation des symptômesGroupes témoins
Prévention
2
#1
Les groupes témoins aident-ils à la prévention ?
Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison.
PréventionGroupes témoins
#2
Comment les groupes témoins influencent-ils la prévention ?
Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention.
Mesures préventivesGroupes témoins
Traitements
2
#1
Quel type de traitement est comparé ?
Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin.
Traitements expérimentauxGroupes témoins
#2
Comment les résultats sont-ils mesurés ?
Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes.
Mesure des résultatsGroupes témoins
Complications
2
#1
Les complications sont-elles observées dans les groupes témoins ?
Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental.
ComplicationsGroupes témoins
#2
Comment les complications sont-elles analysées ?
Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité.
Analyse des complicationsGroupes témoins
Facteurs de risque
2
#1
Les groupes témoins aident-ils à identifier des facteurs de risque ?
Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin.
Facteurs de risqueGroupes témoins
#2
Comment les facteurs de risque sont-ils évalués ?
Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes.
Évaluation des facteurs de risqueGroupes témoins
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Groupes témoins : Questions médicales les plus fréquentes",
"headline": "Groupes témoins : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Groupes témoins : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Groupes témoins"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Méthodes",
"url": "https://questionsmedicales.fr/mesh/D008722",
"about": {
"@type": "MedicalCondition",
"name": "Méthodes",
"code": {
"@type": "MedicalCode",
"code": "D008722",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.581"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Groupes témoins",
"alternateName": "Control Groups",
"code": {
"@type": "MedicalCode",
"code": "D035061",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Steger-Hartmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Steger-Hartmann",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Tania Rivera-Hernandez",
"url": "https://questionsmedicales.fr/author/Tania%20Rivera-Hernandez",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark J Walker",
"url": "https://questionsmedicales.fr/author/Mark%20J%20Walker",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark R Davies",
"url": "https://questionsmedicales.fr/author/Mark%20R%20Davies",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia."
}
},
{
"@type": "Person",
"name": "Alexander Gurjanov",
"url": "https://questionsmedicales.fr/author/Alexander%20Gurjanov",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Characteristics of Diverticular Disease in Caribbean Population: A Control Group Study.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36531833",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/8360837"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparing the effects of SMS-based education with group-based education and control group on diabetes management: a randomized educational program.",
"datePublished": "2022-08-19",
"url": "https://questionsmedicales.fr/article/35986262",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12875-022-01820-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mathematical relationships between control group variability and assay quality metrics.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36841433",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.slasd.2023.02.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Implementation of enhanced recovery in cardiac surgery: An experimental study with the control group.",
"datePublished": "2022-11-14",
"url": "https://questionsmedicales.fr/article/36377227",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/02184923221138504"
}
},
{
"@type": "ScholarlyArticle",
"name": "Perinatal Outcomes After Bariatric Surgery Compared With a Matched Control Group.",
"datePublished": "2023-02-02",
"url": "https://questionsmedicales.fr/article/36735357",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/AOG.0000000000005088"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Méthodes",
"item": "https://questionsmedicales.fr/mesh/D008722"
},
{
"@type": "ListItem",
"position": 4,
"name": "Groupes témoins",
"item": "https://questionsmedicales.fr/mesh/D035061"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Groupes témoins - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Groupes témoins",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Groupes témoins",
"description": "Comment identifier un groupe témoin ?\nQuel est le rôle d'un groupe témoin ?\nComment choisir un groupe témoin ?\nLes groupes témoins sont-ils toujours nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D035061#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Groupes témoins",
"description": "Les groupes témoins montrent-ils des symptômes ?\nComment les symptômes sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Groupes témoins",
"description": "Les groupes témoins aident-ils à la prévention ?\nComment les groupes témoins influencent-ils la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D035061#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Groupes témoins",
"description": "Quel type de traitement est comparé ?\nComment les résultats sont-ils mesurés ?",
"url": "https://questionsmedicales.fr/mesh/D035061#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Groupes témoins",
"description": "Les complications sont-elles observées dans les groupes témoins ?\nComment les complications sont-elles analysées ?",
"url": "https://questionsmedicales.fr/mesh/D035061#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Groupes témoins",
"description": "Les groupes témoins aident-ils à identifier des facteurs de risque ?\nComment les facteurs de risque sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un groupe témoin ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention."
}
},
{
"@type": "Question",
"name": "Quel est le rôle d'un groupe témoin ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Comment choisir un groupe témoin ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins sont-ils toujours nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques."
}
},
{
"@type": "Question",
"name": "Les groupes témoins montrent-ils des symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils évalués ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à la prévention ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison."
}
},
{
"@type": "Question",
"name": "Comment les groupes témoins influencent-ils la prévention ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention."
}
},
{
"@type": "Question",
"name": "Quel type de traitement est comparé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin."
}
},
{
"@type": "Question",
"name": "Comment les résultats sont-ils mesurés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles observées dans les groupes témoins ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles analysées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à identifier des facteurs de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils évalués ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes."
}
}
]
}
]
}
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia.
Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University Xiamen Fujian 361102 China zhangxzh@xmu.edu.cn zijing.li@xmu.edu.cn.
Diverticulosis is not well characterized in the Caribbeans. Our aim was to compare the anatomical presentation of colonic diverticulosis in African Caribbeans (group AC) versus Europeans (group E) and...
We conducted a prospective controlled study involving 274 patients admitted for lower gastrointestinal haemorrhage (LGIH) in France (center 1: Guadeloupe; center 2: La Roche-sur-Yon); 179 cases with d...
AC and E had similar characteristics in terms of age, gender, previous history of LGIH, body mass index, dietary habits, and medications, but AC had significantly poorer hemodynamic parameters at admi...
Our study has shown that diverticulosis was pancolonic in AC and more frequently associated with more severe haemorrhage than the left-sided diverticulosis of Europeans. This anatomical presentation m...
The high prevalence of diabetes and the importance of long-term follow-up of these patients encourage finding an inexpensive and applicable educational method to control the disease. Distance educatio...
This study aimed to compare the effect of SMS- and group-based education in managing diabetes type 2 and compare them with a control group....
A total of 168 patients with diabetes type 2 under the coverage of three family physician clinics were randomly allocated into three groups. The education was conducted in 12 one-hour sessions once a ...
The comparison of the three groups in terms of changes in FBS (P-value: 0.001), 2hppBS (8 P-value: < 0.001) and HbA1c (P-value: < 0.001) were significantly different after 3 months. In pairwise analys...
Although the effect of both educational methods via SMS or group education was better than the control group in controlling diabetes, these two methods were not statistically different. Due to spendin...
Assay quality metrics have been used in various high-throughput screening (HTS) campaigns to indicate assay quality. Z'-factor has become one of the most widely used metrics, along with other metrics ...
The Enhanced Recovery After Cardiac Surgery protocol is the most recent addition to cardiac treatment. In this paper, we aimed to test the safety and viability of this protocol in our hospital to impr...
This study was conducted as an experimental study with a historical control at the Maritime Heart Center, Halifax, Nova Scotia, Canada. In order to quantify the success of this protocol, we measured t...
The primary outcome (Length of Hospital Stay) was reduced from a mean of 8.88 ± 3.50 days in the control group to a mean of 5.13 ± 1.34 days in the Enhanced Recovery After Cardiac Surgery group (...
Enhanced Recovery After Cardiac Surgery protocols were seamlessly integrated into selected cardiac surgical patients, contingent on a high level of interprofessional communication and collaboration....
To evaluate perinatal outcomes associated with pregnancy after bariatric surgery within a large integrated health care system using propensity score matching....
We conducted a retrospective cohort study that evaluated perinatal outcomes in pregnant patients after bariatric surgery from January 2012 through December 2018. History of bariatric surgery was ident...
We identified a case cohort of 1,591 pregnancies in patients after bariatric surgery and a matched cohort of 7,955 pregnancies in patients who had not undergone bariatric surgery. Demographic characte...
Pregnancy after bariatric surgery in a racially and ethnically diverse cohort of patients is associated with decreased risk of preeclampsia, gestational diabetes or impaired fasting glucose, and LGA n...
In type 2 diabetes (T2D) research, the phrase "attention control group" (ACGs) has been used with varying descriptions. We aimed to systematically review the variations in the design and use of ACGs f...
Twenty studies utilizing ACGs were included in the final evaluation. Control group activities had the potential to influence the primary outcome of the study in 13 of the 20 articles. Prevention of co...
Ending the HIV epidemic will require the development of additional effective immune-mediated and nonimmune-mediated means of HIV prevention. Evaluating novel interventions requires large, controlled t...
Three classes of efficacy trial designs are possible: standard of prevention-controlled trials, active-controlled trials, and active-controlled trials augmented with external control data. Recent expe...
Efficacy trials of new HIV prevention interventions are feasible but require careful consideration, given the complexity and dynamic state of the prevention field. While standard of prevention-control...
To determine the effect of Food Sensations for Adults on food literacy behaviors and selected dietary behaviors....
A quasi-experimental design using preprogram and postprogram questionnaires over 4 weeks with a control group (n = 75) matched for sex, age group, and socioeconomic disadvantage to program participant...
Postprogram, Food Sensations for Adults participants reported modest yet statistically significant score improvements in 2 of the 3 domains of food literacy behaviors in the plan and manage (12.4%) an...
Quasi-experimental designs indicate food literacy programs can produce modest short-term changes across a range of food literacy and dietary behaviors....
Little is known about the impact of control group therapy on clinical benefit scales such as American Society of Clinical Oncology Value Framework (ASCO-VF), European Society for Medical Oncology Magn...
Many patients have prolonged symptoms after COVID-19 infection, which can affect patient quality of life (QOL). The aim of this study is to determine the quality of life in patients with long COVID, c...
The study was a prospective cross-sectional study using an anonymous online survey. The SF-36 questionnaire was chosen for quality of life measurement. The survey was distributed through the Facebook ...
There was a significant difference in physical function, with a mean score of 94.9 (±9.4) among the students, compared to long COVID patients with a mean score of 66.2 (±25.4) (...
Patients with long COVID had a lower quality of life compared to the healthy control group, and this was associated with the negative effect of long-COVID. Lower quality of life in patients with long ...